Clinical Trial: EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Safety and Efficacy of a Novel Modified Release Formulation of Oxcarbazepine (OXC MR) vs an Immediate Release Oxcarbazepine (OXC IR) Product in Patients With Partial Epilepsy

Brief Summary: This study is intended to investigate the safety and efficacy of a novel formulation of oxcarbazepine that is released more slowly than the current formulation. The study medication will be used as a treatment against partial epilepsy.

Detailed Summary: This is a multi-centre, randomized, open-label, flexible-titration, controlled, parallel-group study to investigate the safety and efficacy of a novel modified release formulation of oxcarbazepine (OXC MR) compared to an immediate release oxcarbazepine (OXC IR) product in patients with partial epilepsy. Adult patients of both gender, aged at least 18 years with refractory partial epilepsy, with or without secondary generalisation receiving a stable background treatment with daily dosages of exactly 900 or 1200 or 1500 mg Oxcarbazepine will be enrolled. Concomitant medication consisting of maximal 2 additional AEDs (vagus nerve stimulator included) is allowed and must be kept stable throughout the study. Patients, who agree to participate, will first sign and date the informed consent and undergo an evaluation at screening visit to determine eligibility. Those patients who qualify will be enrolled in the study, assigned a patient ID, and will enter the 4-week baseline period. Each patient will receive a seizure diary to record the number of seizures during the baseline period. For Visit 1 the patient will return to the clinic and complete all baseline procedures. Patients who have met the entry criteria will be randomised. The two treatment groups consist of 50 patients each, one group to be treated with OXC MR b.i.d. and the other to be treated with OXC IR b.i.d. in a 1:1 randomization. Following assignment to one of both treatment groups the patient will enter the dose-titration phase. From Visit 1 (Study Day 1) a total daily dose of 1200 mg /1500 mg /1800 mg oxcarbazepine will be given to the randomised patients. From Day 6 the dosage will be titrated to a maximum total daily dose of 2700 mg in steps of 300 mg every 6th day. Patients who experienced intolerable adverse events could reduce their daily dose by 150 mg on the 2nd day of up-titration for the remainder of the treatment period. In case the reduced dosage will also not be tolerated, in a second step the d
Sponsor: Desitin Arzneimittel GmbH

Current Primary Outcome: Maintenance dosage where dose up-titration has to be discontinued due to AEs [ Time Frame: whenever criterion is met ]

Original Primary Outcome: Maintenance dosage where dose up-titration has to be discontinued due to AEs

Current Secondary Outcome:

  • Number of seizures during the trial [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ]
  • OXC and MHD plasma levels obtained from 6 patients per centre [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ]
  • Adverse event profile Plus (AEP) questionnaire-score [ Time Frame: at each patient contact ]
  • EpiTrack [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ]
  • Vital Signs and ECG [ Time Frame: Visit 1, Visit 2, Final Visit and each unscheduled visit ]
  • Laboratory parameters (hematology, serum chemistry, coagulation, urinalysis) [ Time Frame: Visit 1, Visit 2, Final Visit ]


Original Secondary Outcome:

  • Number of seizures during the trial
  • OXC and MHD plasma levels obtained from 6 patients per centre
  • Adverse event profile Plus (AEP) questionnaire-score
  • EpiTrack
  • Systolic and diastolic blood pressure in supine and standing position
  • Pulse rate
  • ECG
  • Serum chemistry
  • Coagulation
  • Hematology
  • Urinalysis


Information By: Desitin Arzneimittel GmbH

Dates:
Date Received: October 23, 2006
Date Started: October 2006
Date Completion:
Last Updated: April 14, 2010
Last Verified: January 2009